|
|
|
| Research progress on novel molecular marker of glioma |
| LI Xiaorong1 WANG Hongkun2 BIAN Wei1 ZHENG Huixia2 XIAO Hong2 |
1.The First Clinical Medical College, Shanxi Medical University, Shanxi Province, Taiyuan 030000, China;
2.Department of Pathology, the First Hospital of Shanxi Medical University, Shanxi Province, Taiyuan 030000, China
|
|
|
|
Abstract Glioma is an intracranial malignant tumor with high morbidity and mortality, which causes a huge burden to public health. At present, relying solely on imaging and pathological classification based on traditional biopsy tissue morphology cannot meet the needs of clinical diagnosis and treatment. Therefore, it is urgent to explore auxiliary diagnostic tools with higher sensitivity and stronger specificity. In recent years, the clinical application of molecular marker has become a research hotspot, which helps to clarify disease classification and ensure early detection, diagnosis, and treatment. This article summarizes the potential roles of some genetic molecular markers in disease diagnosis and prognosis prediction, aiming to lay a theoretical foundation for the clinical application of glioma and make personalized and precise treatment possible.
|
|
|
|
|
|
[1] Ostrom QT，Gittleman H，Stetson L，et al. Epidemiology of intracranial gliomas [J]. Prog Neurol Surg，2018，30：1-11.
[2] Shrivastava R，Gandhi P，Gothalwal R. The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy：current status and future directions [J]. Clin Transl Oncol，2022，24（9）：1702-1714.
[3] Komori T. The 2021 WHO classification of tumors，5th edition，central nervous system tumors：a short review [J]. Brain Nerve，2022，74（6）：803-809.
[4] Pienkowski T，Kowalczyk T，Garcia-Romero N，et al. Proteomics and metabolomics approach in adult and pediatric glioma diagnostics [J]. Biochim Biophys Acta Rev Cancer，2022，1877（3）：188721.
[5] Huang LE. Impact of CDKN2A/B homozygous deletion on the prognosis and biology of IDH-mutant glioma [J]. Biome- dicines，2022，10（2）：246.
[6] Hansen LJ，Yang R，Roso K，et al. MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization [J]. Sci Rep，2022，12（1）：4183.
[7] Sasaki S，Takeda M，Hirose T，et al. Correlation of MTAP immunohistochemistry with CDKN2A status assessed by fluorescence in situ hybridization and clinicopathological features in CNS WHO grade 2 and 3 meningiomas：a single center cohort study [J]. J Neuropathol Exp Neurol，2022，81（2）： 117-126.
[8] Satomi K，Ohno M，Matsushita Y，et al. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma [J]. Mod Pathol，2021，34（4）：688-700.
[9] Onishi S，Yamasaki F，Kuraoka K，et al. Diagnostic and therapeutic challenges of glioblastoma as an initial malignancy of constitutional mismatch repair deficiency （CMMRD）：two case reports and a literature review [J]. BMC Med Genomics，2023，16（1）：6.
[10] Ammendola S，Broggi G，Barresi V. IDH-mutant diffuse gliomas：tips and tricks in the era of genomic tumor classification [J]. Histol Histopathol，2023，38（7）：739-753.
[11] Suwala AK，Stichel D，Schrimpf D，et al. Primary mismatch repair deficient IDH-mutant astrocytoma （PMMRDIA） is a distinct type with a poor prognosis [J]. Acta Neuropathol，2021，141（1）：85-100.
[12] Zeng J，Xi SY，Wang F，et al. L1CAM High expression associates with poor prognosis in glioma but does not correlate with C11orf95-RELA fusion [J]. Biomed Res Int，2020， 2020：1353284.
[13] Hu Y，Zhang B，Lu P，et al. The positive regulatory loop of TCF4N/p65 promotes glioblastoma tumourigenesis and chemosensitivity [J]. Clin Transl Med，2022，12（9）：e1042.
[14] Chinnam D，Gupta K，Kiran T，et al. Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications [J]. Brain Tumor Pathol，2022，39（3）：151-161.
[15] Puerkaiti P，Fan JJ，Ma BL. Effect of overexpression of integrin beta2 on clinical prognosis in triple negative breast cancer [J]. Zhonghua Yi Xue Za Zhi，2020，100（30）：2358- 2362.
[16] Li J，Zhang Z，Feng X，et al. Stanniocalcin-2 promotes cell EMT and glycolysis via activating ITGB2/FAK/SOX6 signaling pathway in nasopharyngeal carcinoma [J]. Cell Biol Toxicol，2022，38（2）：259-272.
[17] Liu H，Wang J，Luo T，et al. Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma（LGG） [J]. Front Endocrinol （Lausanne），2022，13：1106120.
[18] Xu H，Zhang A，Han X，et al. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas [J]. Cancer Immunol Immunother，2022，71（3）：645-660.
[19] Kim YH，Byun YJ，Kim WT，et al. CDC6 mRNA expression is associated with the aggressiveness of prostate cancer [J]. J Korean Med Sci，2018，33（47）：e303.
[20] Wang F，Zhao F，Zhang L，et al. CDC6 is a prognostic biom- arker and correlated with immune infiltrates in glioma [J]. Mol Cancer，2022，21（1）：153.
[21] 赵浩.CDC6调节脑胶质瘤细胞增殖和侵袭及其作用机制研究[D].济南：山东大学，2021.
[22] Lin JZ，Lin N，Zhao WJ. Identification and validation of a six-lncRNA prognostic signature with its ceRNA networks and candidate drugs in lower-grade gliomas [J]. Genomics，2020，112（5）：2990-3002.
[23] Li J，Liang R，Song C，et al. Prognostic and clinicopathological significance of long non-coding RNA in glioma [J]. Neurosurg Rev，2020，43（1）：1-8.
[24] Shen J，Hodges TR，Song R，et al. Serum HOTAIR and GAS5 levels as predictors of survival in patients with gliob- lastoma [J]. Mol Carcinog，2018，57（1）：137-141.
[25] Xu X，Liang Y，Gareev I，et al. LncRNA as potential biomar- ker and therapeutic target in glioma [J]. Mol Biol Rep，2023， 50（1）：841-851.
[26] Ayoub G，Chalhoub E，Kourie HR. BRAF：a biomarker not to be missed in glioblastoma [J]. Per Med，2022，19（2）：79- 82.
[27] Jin T，Li D，Yang T，et al. PTPN1 promotes the progression of glioma by activating the MAPK/ERK and PI3K/AKT pathways and is associated with poor patient survival [J]. Oncol Rep，2019，42（2）：717-725.
[28] Bar EE，Lin A，Tihan T，et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma [J]. J Neuropathol Exp Neurol，2008，67（9）：878-887.
[29] Wu Y，Wang H，Wei D. Oncogenic magnesium transporter 1 upregulates programmed death-1-ligand 1 expression and contributes to growth and radioresistance of glioma cells through the ERK/MAPK signaling pathway [J]. Bioengineered，2022，13（4）：9575-9587.
[30] Friedman JS，Hertz CAJ，Karajannis MA，et al. Tapping into the genome：the role of CSF ctDNA liquid biopsy in glioma [J]. Neurooncol Adv，2022，4（Suppl 2）：ii33-ii40. |
|
|
|
